Solid Biosciences is a gene therapy company developing treatments for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, and inherited cardiomyopathies. The company's candidates use modified adeno-associated viral vectors to deliver functional gene copies to affected tissues, incorporating proprietary capsid technology, therapeutic transgenes, and tissue-specific promoters. Solid generates revenue through milestone payments and royalties from a licensing program around its POLARIS-101™ capsid platform, which has been licensed to over 50 academic institutions and biotechnology companies, while developing its own pipeline of in-house gene therapy programs targeting patient populations with small but severely underserved medical needs.